[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 0, () 308-310 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
����ϸ����������
��������,CC
Ƥ������
���������������
���Ƿ�
������
PubMed
Article by
Article by

����ϸ��������ѧ����������Ƥ����

���Ƿ�, ������

�㽭��ѧҽѧԺ������ԺƤ����, ����310009

ժҪ��

����ϸ��������ѧ����������һ�־���ϸ����Դ����������,������������CC����(���¼���)����������ͬ���������������ͬ���Ļ�ѧ�յ�����,��Ҫ��������ϸ��������ϸ����������ͻ״ϸ���Լ���Ȼɱ��ϸ�������Ž��������仯ѧ���ʵķ��ֺ�����������ϸ�����ӽ鵼����֢��Ӧ�Լ������Լ��������õ������о�,����ϸ��������ѧ������������ʾ����DZ�ڵ��ٴ����塣

�ؼ����� ����ϸ����������   ��������,CC   Ƥ������  

Abstract:

Keywords:
�ո����� 2005-01-27 �޻�����  ����淢������  
DOI:
������Ŀ:

ͨѶ����:
���߼��:

�ο����ף�
[1] Zlotnik A, Yoshie O. Chemokines:a new classification system and their role in immunity. Immunity, 2000, 12:121-127.
[2] Godiska R, Chantry D, Raport C J, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes,monocyte-derived dendritic cells, and natural killer cells. J Exp Med, 1997, 185:1595-1604.
[3] Imai T, Chantry D, Raport CJ, et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem, 1998, 273:1764-1768.
[4] Struyf S, Proost P, Sozzani S,et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol, 1998, 161:2672-2675.
[5] Pal R, Garzino-Demo A, Markham PD, et al. Inhibition of HIV-1infection by the beta-chemokine MDC. Science, 1997, 278:695-698.
[6] Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol, 2002, 32:1403-1413.
[7] Campbell JJ, Pan J, Butcher EC. Cutting edge:developmental switches in chemokine responses during T cell maturation. J Immunol, 1999, 163:2353-2357.
[8] Power CA, Clemetson JM, Clemetson K J, et al. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine,1995, 7:479-482.
[9] Suttitanamongkol S, Gear AR. ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC. FEBS Lett, 2001, 490:84-87.
[10] Kakinuma T, Nakamura K, Wakugawa M, et al. Serum macrophagederived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol, 2002, 127:270-273.
[11] Galli G, Chantry D, Annunziato F, et al. Macrophage-derived chemokine production by activated human T cells in vitro and in vivo:preferential association with the production of type 2 cytokines. Eur J Immunol, 2000, 30:204-210.
[12] Furukawa H, Takahashi M, Nakamura K, et al. Effect of an antiallergic drug (Olopatadine hydrochloride)on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci, 2004, 36:165-172.
[13] Horikawa T, Nakayama T, Hikita I, et al. IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol, 2002,14:767-773.
[14] Xiao T, Kagami S, Saeki H, et al. Both IL-4 and IL-13 inhibit the TNF-alpha and IFN-gamma enhanced MDC production in a human keratinocyte cell line, HaCaT cells. J Dermatol Sci, 2003, 31:111.
[15] Grewe M, Bruijnzeel-Koomen CA, Schopf E, et al. A role for Th1and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today, 1998, 19:359-361.
[16] Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines(TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci, 2004, 34:201.
[17] Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis:relationship with cutaneous and internal organ involvement. Clin Exp Immunol, 2004, 138:540-546.
[18] Fujii H, Shimada Y, Hasegawa M, et al. Serum levels of a Th1chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC,are elevated in patients with systemic sclerosis. J Dermatol Sci,2004, 35:43-51.
[19] Cota M, Mengozzi M, Vicenzi E,et al. Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proc Natl Acad Sci U S A, 2000,97:9162-167.
�������������
1�����Ƿ�, ������.����ϸ��������ѧ����������Ƥ����[J]. ����Ƥ���Բ�ѧ��־, 0,(): 308-310
2�����Ƿ�, ������.����ϸ��������ѧ����������Ƥ����[J]. ����Ƥ���Բ�ѧ��־, 2005,31(5): 308-310

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־